Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

EAST RUTHERFORD, N.J., Aug. 2, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports second quarter results for the period ended June 30, 2011.

Highlights

  • Reported sales increased by 17.6%, and excluding the impact of foreign currency, sales increased 6.9% compared to the second quarter of 2010.
  • EBITDA was $13.2 million in the second quarter of 2011, an increase of 8.6% compared to $12.1 million in the second quarter of 2010.
  • Debt, net of cash was $75.5 million at the end of the second quarter of 2011, an improvement of $7.1 million during the quarter which includes a positive $0.4 million currency impact on foreign cash balances.

  • Second Quarter of 2011 Operating Results – Continuing OperationsSales in the second quarter of 2011 of $67.5 million were 17.6% higher than the second quarter of 2010. Excluding a 10.7% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales increased 6.9%.  The increase is primarily due to higher sales of certain larger custom manufacturing products and higher volumes of generic APIs.  These increases were partially offset by the timing of orders for certain products, lower custom development revenues and lower pricing across several product categories.  

    Second quarter of 2011 Gross Margin decreased to 28.2% from 31.2% during the second quarter of 2010, with foreign currency unfavorably impacting gross margin by 2.3% in the second quarter of 2011.  Gross margins were negatively impacted by lower pricing partially offset by higher sales and production volumes and lower production costs.  

    Selling, General and Administrative Expenses in the second quarter of 2011 were $9.2 million compared to $8.2 million in the same period last year.  The increase is primarily due to unfavorable foreign exchange.

    Research and Development ("R&D") Expenses decreased to $2.6 million in the second quarter of 2011 from $2.8 million in the second quarter of 2010.

    Operating Profit increased to $7.3 million in the second quarter of 2011 from $6.9 million in the second quarter of 2010.  The increase in Operating Profit was driven primarily by higher sales volumes and lower production costs partially offset by lower pricing and unfavorable foreign exchange.

    Net Interest Expense decreased to $0.6 million in the second quarter of 2011 from $1.2 million in the second quarter of 2010.  This decrease is primarily due to the maturing of the Company's higher fixed interest rate swaps in October 2010.

    The Provision for Income Taxes totaled $1.9 million in the second quarter of 2011.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

    Income from continuing operations for the second quarter of 2011 was $4.8 million or $0.16 per share compared to $3.7 million or $0.12 per share in the second quarter of 2010.

    Capital expenditures and depreciation for the second quarter of 2011 were $3.0 million and $5.8 million compared to $2.4 million and $5.2 million in the second quarter of 2010, respectively.

    Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with our second quarter and year to date performance with sales volumes significantly higher year over year.  Similar to the first quarter, we saw increases in revenues for some of our larger custom manufacturing products and continued strong orders for our generic APIs.  Although profit margins were negatively impacted by foreign exchange, tiered pricing arrangements and production inefficiencies at one of our plants, a continued focus on cost reductions helped mitigate those impacts and contributed to our strong cash flow in the quarter."

    Guidance – Continuing OperationsThe Company continues to expect that sales for 2011, excluding the impact of foreign currency, will increase between 3% and 7% versus 2010, and that full year 2011 EBITDA will be between $43 and $49 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Cambrex Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Cambrex Zenara's net results as Equity in Losses of Partially-Owned Affiliate.  For 2011, the Company continues to expect Cambrex Zenara to have revenues in the low to mid single digit millions and a small EBITDA loss.

    Capital expenditures are expected to be approximately $14 to $17 million and depreciation is now expected to be $22 to $24 million in 2011, a $1 million increase over prior guidance due to foreign exchange.

    The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's second quarter 2011 Form 10-Q is filed with the SEC.

    Conference Call and WebcastThe Conference Call to discuss second quarter of 2011 results will begin at 8:30 a.m. Eastern Time on Wednesday, August 3, 2011 and last approximately 45 minutes.  Those wishing to participate should call 1-888-471-3840 for domestic and +1-719-457-2647 for international.  Please use the pass code 1438939 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Wednesday, August 10, 2011 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 1438939 to access the replay.  

    Forward Looking StatementsThis document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected performance, especially expectations with respect to sales, gross margins, operating expenses, earnings per share, cash flows, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2010, captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2010, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

    For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

    About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended June 30, 2011 and 2010(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales

    $

    67,484$

    57,403Commissions, Allowances and Rebates523376Net Sales66,96157,027Other1,4211,190Net Revenues68,38258,217Cost of Goods Sold49,32573.1%40,28470.2%Gross Profit19,05728.2%17,93331.2%Operating ExpensesSelling, General and Administrative Expenses9,19113.6%8,18414.3%Research and Development Expenses2,5723.8%2,8414.9%Total Operating Expenses11,76317.4%11,02519.2%Operating Profit7,29410.8%6,90812.0%Other Expenses/(Income):Interest Expense, net6051,171Other (Income)/Expenses, net(282)14Equity in Losses of Partially-Owned Affiliate303-Income Before Income Taxes6,6689.9%5,72310.0%Provision for Income Taxes1,9112,057Income from Continuing Operations

    $

    4,7577.0%$

    3,6666.4%Income  from Discontinued Operations, Net of Tax-1,105Net Income

    $

    4,7577.0%$

    4,7718.3%Basic Earnings per Share of Common Stock:   Income from Continuing Operations

    $

    0.16$

    0.12   Income from Discontinued Operations, Net of Tax

    $

    -$

    0.04   Net Income

    $

    0.16$

    0.16Diluted Earnings per Share of Common Stock:   Income from Continuing Operations

    $

    0.16$

    0.12   Income from Discontinued Operations, Net of Tax

    $

    -$

    0.04   Net Income

    $

    0.16$

    0.16Weighted Average Shares OutstandingBasic29,41929,333Diluted29,49329,404CAMBREX CORPORATIONStatements of Profit and LossFor the Six Months Ended June 30, 2011 and 2010(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales

    $

    129,138$

    113,558Commissions, Allowances and Rebates814712Net Sales128,324112,846Other6431,464Net Revenues128,967114,310Cost of Goods Sold92,45571.6%81,88472.1%Gross Profit36,51228.3%32,42628.6%Operating ExpensesSelling, General and Administrative Expenses18,27914.1%16,98015.0%Research and Development Expenses5,6324.4%4,8264.2%Total Operating Expenses23,91118.5%21,80619.2%Operating Profit12,6019.8%10,6209.4%Other Expenses/(Income):Interest Expense, net1,1782,369Other (Income)/Expenses, net(285)17Equity in Losses of Partially-Owned Affiliate667-Income Before Income Taxes11,0418.5%8,2347.3%Provision for Income Taxes3,4292,885Income from Continuing Operations

    $

    7,6125.9%$

    5,3494.7%(Loss)/Income  from Discontinued Operations, Net of Tax(146)1,105Net Income

    $

    7,4665.8%$

    6,4545.7%Basic Earnings/(Loss) per Share of Common Stock:   Income from Continuing Operations

    $.26$.18   (Loss)/Income from Discontinued Operations, Net of Tax

    $

      (0.01)$.04   Net Income

    $.25$.22Diluted Earnings/(Loss) per Share of Common Stock:   Income from Continuing Operations

    $.26$.18   (Loss)/Income from Discontinued Operations, Net of Tax

    $

      (0.01)$.04   Net Income

    $.25$.22Weighted Average Shares OutstandingBasic29,43329,324Diluted29,49029,402CAMBREX CORPORATIONConsolidated Balance SheetsAs of June 30, 2011 and December 31, 2010(in thousands)June 30,December 31,Assets20112010Cash and Cash Equivalents

    $

    40,911 $

    29,614Trade Receivables, net38,27339,025Inventories, net67,96161,408Prepaid Expenses and Other Current Assets7,8915,082  Total Current Assets155,036135,129Property, Plant and Equipment, net152,057150,483Goodwill40,17737,694Intangible Assets, net4,8984,687Investment in Partially-Owned Affiliate18,87819,709Other Non-Current Assets2,9944,049  Total Assets

    $

    374,040 $

    351,751Liabilities and Stockholders' EquityAccounts Payable

    $

    19,619 $

    19,480Accrued Expenses and Other Current Liabilities36,92633,503Current Portion of Long-term Debt116,400-  Total Current Liabilities172,94552,983Long-term Debt-115,900Deferred Income Taxes18,79017,893Accrued Pension and Postretirement Benefits40,20643,921Other Non-Current Liabilities13,33213,419  Total Liabilities

    $

    245,273 $

    244,116  Stockholders’ Equity

    $

    128,767 $

    107,635  Total Liabilities and Stockholders’ Equity

    $

    374,040 $

    351,751CAMBREX CORPORATIONReconciliation of EBITDAFor the Quarters and Six Months Ended June 30, 2011 and 2010(in thousands)Second Quarter 2011Second Quarter 2010Operating Profit

    $

    7,294$

    6,908Depreciation and Amortization5,8785,226EBITDA

    $

    13,172$

    12,134Six Months 2011Six Months 2010Operating Profit

    $

    12,601$

    10,620Depreciation and Amortization11,60310,610EBITDA

    $

    24,204$

    21,230
    '/>"/>

    SOURCE Cambrex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Cambrex Reports Third Quarter 2010 Results
    2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
    3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
    4. Cambrex Reports First Quarter 2009 Results
    5. Cambrex Receives Notice Regarding NYSE Listing
    6. Cambrex Reports Third Quarter 2008 Results
    7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
    8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
    9. Neurocrine Biosciences Reports Second Quarter 2011 Results
    10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
    11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... 11, 2016  Wellcentive today announced it has ... Oregon -based community care organization (CCO) with ... analytics, quality reporting and care management solutions and ... team of quality managers, analysts and care managers ... groups serving FamilyCare members. ...
    (Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
    (Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells Group, ... Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and other biological ... Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, ...
    (Date:2/10/2016)... February 10, 2016 Early-career researchers ... Peru , Uganda and ... in health and nutrition   Indonesia , ... and Yemen are being honored for ... They are also celebrated for mentoring young women scientists who are pursuing ...
    Breaking Biology Technology:
    (Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
    (Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
    (Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated ... human interface solutions, today announced sampling of S1423, ... for wearables and small screen applications including smartwatches, ... printers. Supporting round and rectangular shapes, as well ... excellent performance with moisture on screen, while wearing ...
    Breaking Biology News(10 mins):